Key facts
- PtBio’s last known valuation is $31.3M (Sep 2025).
- It has raised $5.8M; the latest was Later Stage VC ($1.8M) in Sep 2025.
- Notable investors include Japan External Trade Organization, Sunway iLabs, Hiroshima Venture Capital, Chugin Capital Partner, Hiroshima Unicorn 10 — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for PtBio
- ·The full record, as it builds
Funding rounds
No funding rounds for PtBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PtBio
Developer of a bioinformatics platform designed to manipulate and study deoxyribonucleic acid (DNA) sequences. The company's tool offers alignment, variant calling, and functional annotation to identify genes involved in target functions through extensive genome information and conducts mutational analysis to verify and confirm desired genetic mutations, enabling biotechnology and pharmaceutical companies to design and test new products, improve inherited traits, and accelerate research and development timelines.
- Sector
- Healthcare
- HQ
- Higashi-Hiroshima, Japan
- Founded
- 2019
- Employees
- 15
- Website
- pt-bio.com/
- Ownership
- Privately Held (backing)
PtBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PtBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PtBio in its N-PORT filings yet. We sweep new filings monthly.